Company
Every investor coverage indicates participated in a round Rockwell Securities Limited raised.
Companies Rockwell Securities Limited acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Rockwell Securities Limited. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures' letter to Arana Therapeutics shareholders covers Cephalon's proposed cash takeover, an attached dividend, the board's recommendation to accept, and Cephalon's pre-bid purchase of a 19.8% stake.
Cephalon has announced plans to buy out Arana Therapeutics shareholders at $1.40 a share, potentially $1.45, valuing the ASX-listed target around $318 million; its independent directors back the bid unless a better one emerges.